Bunkerhill AVC vs Lung AI

Exo's Lung AI, integrated with the handheld Exo Iris ultrasound device, offers on-device AI processing and guided image capture, making it highly portable and accessible for real-time decisions at the point of care. This direct integration and real-time feedback likely contribute to a more immediate and intuitive user experience, especially for clinicians with varying expertise levels. Bunkerhill AVC integrates with existing EHRs and clinical archives, which is valuable for workflow automation but may involve a steeper learning curve for new users interacting with a generative AI platform for clinical reasoning and action.

Bunkerhill AVC has FDA clearance specifically for the early detection and quantification of aortic valve calcification (AVC) from chest CTs, and has expanded its clearances to include coronary artery calcification (CAC) on both non-contrast and contrast-enhanced CTs. This provides a clear, validated clinical application for identifying at-risk patients for cardiovascular disease. While Exo's Lung AI also has FDA clearance for detecting pleural effusion and consolidation/atelectasis, and has shown to improve diagnostic accuracy, Bunkerhill's focus on opportunistic screening for a prevalent and serious condition like aortic stenosis offers significant potential for proactive disease management and improved patient outcomes on a broader scale.

Both tools require contacting the company for pricing, but Bunkerhill Health has successfully secured a national billing code (G0680) and associated payment under the Hospital Outpatient Prospective Payment System (OPPS) for algorithmic analysis of coronary artery calcium (CAC) and aortic valve calcification (AVC) on chest CT scans, effective April 1, 2026. This reimbursement pathway provides a clearer financial framework for health systems, potentially making Bunkerhill AVC a more financially viable and valuable investment in the long term compared to Lung AI, for which specific reimbursement information was not readily available.

Bunkerhill Health's Carebricks platform is designed for integration with full Electronic Health Records (EHRs) and clinical archives, enabling customizable AI agents for diverse workflows, including incidental findings management, prior authorization, and registry submission. This broad integration capability and the ability to deploy AI agents for various clinical and operational tasks demonstrate a higher level of enterprise readiness for system-wide adoption and impact. Exo's Lung AI, while FDA-cleared and on-device, is primarily focused on its handheld ultrasound platform, which may limit its broader enterprise-wide workflow automation capabilities.

Bunkerhill Health's Carebricks platform utilizes generative AI for clinical reasoning and action, allowing for the creation of customizable AI agents that can reason across a patient's full medical history and execute actions like initiating referrals and coordinating follow-up care. This generative AI approach and the ability to build diverse, agentic workflows represent a significant innovation in applying AI beyond simple detection to more complex clinical decision support and automation. While Exo's on-device AI for real-time ultrasound interpretation is innovative for point-of-care, Bunkerhill's platform offers a broader, more adaptable, and intelligent automation framework.

Neither the provided structured facts nor the web search results offered specific details regarding the depth, availability, or quality of support and documentation for either Bunkerhill AVC or Lung AI. Both companies are established in the healthcare AI space, suggesting a baseline level of support, but without further information, a definitive winner cannot be determined.